NASDAQ:ANIK

Anika Therapeutics Competitors

$40.90
+0.48 (+1.19 %)
(As of 04/14/2021 01:36 PM ET)
Add
Compare
Today's Range
$40.64
Now: $40.90
$41.66
50-Day Range
$32.49
MA: $37.40
$41.05
52-Week Range
$27.53
Now: $40.90
$47.47
Volume2,662 shs
Average Volume147,096 shs
Market Capitalization$586.10 million
P/E RatioN/A
Dividend YieldN/A
Beta1.1

Competitors

Anika Therapeutics (NASDAQ:ANIK) Vs. ALGN, WST, COO, XRAY, HAE, and QDEL

Should you be buying ANIK stock or one of its competitors? Companies in the sub-industry of "health care supplies" are considered alternatives and competitors to Anika Therapeutics, including Align Technology (ALGN), West Pharmaceutical Services (WST), The Cooper Companies (COO), DENTSPLY SIRONA (XRAY), Haemonetics (HAE), and Quidel (QDEL).

Anika Therapeutics (NASDAQ:ANIK) and Align Technology (NASDAQ:ALGN) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, profitability, earnings, dividends, valuation, risk and analyst recommendations.

Earnings and Valuation

This table compares Anika Therapeutics and Align Technology's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Anika Therapeutics$114.51 million5.12$27.19 million$2.0519.95
Align Technology$2.41 billion19.67$442.78 million$4.96120.59

Align Technology has higher revenue and earnings than Anika Therapeutics. Anika Therapeutics is trading at a lower price-to-earnings ratio than Align Technology, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Anika Therapeutics and Align Technology's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Anika Therapeutics-5.18%2.63%1.91%
Align Technology76.00%68.99%46.64%

Insider and Institutional Ownership

95.0% of Anika Therapeutics shares are owned by institutional investors. Comparatively, 85.8% of Align Technology shares are owned by institutional investors. 2.5% of Anika Therapeutics shares are owned by company insiders. Comparatively, 1.2% of Align Technology shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Risk and Volatility

Anika Therapeutics has a beta of 1.1, indicating that its share price is 10% more volatile than the S&P 500. Comparatively, Align Technology has a beta of 1.68, indicating that its share price is 68% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and price targets for Anika Therapeutics and Align Technology, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Anika Therapeutics00103.00
Align Technology13902.62

Anika Therapeutics presently has a consensus target price of $43.00, suggesting a potential upside of 4.72%. Align Technology has a consensus target price of $501.3333, suggesting a potential downside of 15.77%. Given Anika Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Anika Therapeutics is more favorable than Align Technology.

Summary

Align Technology beats Anika Therapeutics on 10 of the 14 factors compared between the two stocks.

Anika Therapeutics (NASDAQ:ANIK) and West Pharmaceutical Services (NYSE:WST) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, risk and analyst recommendations.

Risk and Volatility

Anika Therapeutics has a beta of 1.1, indicating that its stock price is 10% more volatile than the S&P 500. Comparatively, West Pharmaceutical Services has a beta of 1.13, indicating that its stock price is 13% more volatile than the S&P 500.

Profitability

This table compares Anika Therapeutics and West Pharmaceutical Services' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Anika Therapeutics-5.18%2.63%1.91%
West Pharmaceutical Services14.69%19.01%12.78%

Earnings & Valuation

This table compares Anika Therapeutics and West Pharmaceutical Services' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Anika Therapeutics$114.51 million5.12$27.19 million$2.0519.95
West Pharmaceutical Services$1.84 billion12.18$241.70 million$3.2493.66

West Pharmaceutical Services has higher revenue and earnings than Anika Therapeutics. Anika Therapeutics is trading at a lower price-to-earnings ratio than West Pharmaceutical Services, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Anika Therapeutics and West Pharmaceutical Services, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Anika Therapeutics00103.00
West Pharmaceutical Services01202.67

Anika Therapeutics currently has a consensus price target of $43.00, suggesting a potential upside of 4.72%. West Pharmaceutical Services has a consensus price target of $310.00, suggesting a potential upside of 2.35%. Given Anika Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Anika Therapeutics is more favorable than West Pharmaceutical Services.

Insider & Institutional Ownership

95.0% of Anika Therapeutics shares are owned by institutional investors. Comparatively, 92.6% of West Pharmaceutical Services shares are owned by institutional investors. 2.5% of Anika Therapeutics shares are owned by insiders. Comparatively, 1.6% of West Pharmaceutical Services shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

West Pharmaceutical Services beats Anika Therapeutics on 10 of the 14 factors compared between the two stocks.

The Cooper Companies (NYSE:COO) and Anika Therapeutics (NASDAQ:ANIK) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, risk, earnings, valuation and institutional ownership.

Volatility & Risk

The Cooper Companies has a beta of 0.82, suggesting that its stock price is 18% less volatile than the S&P 500. Comparatively, Anika Therapeutics has a beta of 1.1, suggesting that its stock price is 10% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings for The Cooper Companies and Anika Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
The Cooper Companies04602.60
Anika Therapeutics00103.00

The Cooper Companies currently has a consensus price target of $384.25, suggesting a potential downside of 1.10%. Anika Therapeutics has a consensus price target of $43.00, suggesting a potential upside of 4.72%. Given Anika Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Anika Therapeutics is more favorable than The Cooper Companies.

Insider & Institutional Ownership

95.8% of The Cooper Companies shares are owned by institutional investors. Comparatively, 95.0% of Anika Therapeutics shares are owned by institutional investors. 1.4% of The Cooper Companies shares are owned by insiders. Comparatively, 2.5% of Anika Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares The Cooper Companies and Anika Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
The Cooper Companies9.81%12.79%7.20%
Anika Therapeutics-5.18%2.63%1.91%

Earnings and Valuation

This table compares The Cooper Companies and Anika Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
The Cooper Companies$2.43 billion7.87$238.40 million$9.6440.37
Anika Therapeutics$114.51 million5.12$27.19 million$2.0519.95

The Cooper Companies has higher revenue and earnings than Anika Therapeutics. Anika Therapeutics is trading at a lower price-to-earnings ratio than The Cooper Companies, indicating that it is currently the more affordable of the two stocks.

Summary

The Cooper Companies beats Anika Therapeutics on 10 of the 14 factors compared between the two stocks.

Anika Therapeutics (NASDAQ:ANIK) and DENTSPLY SIRONA (NASDAQ:XRAY) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, dividends, valuation, profitability, risk, earnings and institutional ownership.

Risk and Volatility

Anika Therapeutics has a beta of 1.1, suggesting that its share price is 10% more volatile than the S&P 500. Comparatively, DENTSPLY SIRONA has a beta of 0.98, suggesting that its share price is 2% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Anika Therapeutics and DENTSPLY SIRONA, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Anika Therapeutics00103.00
DENTSPLY SIRONA15702.46

Anika Therapeutics presently has a consensus target price of $43.00, suggesting a potential upside of 4.72%. DENTSPLY SIRONA has a consensus target price of $55.3333, suggesting a potential downside of 14.87%. Given Anika Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Anika Therapeutics is more favorable than DENTSPLY SIRONA.

Insider and Institutional Ownership

95.0% of Anika Therapeutics shares are held by institutional investors. Comparatively, 96.0% of DENTSPLY SIRONA shares are held by institutional investors. 2.5% of Anika Therapeutics shares are held by company insiders. Comparatively, 0.5% of DENTSPLY SIRONA shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Anika Therapeutics and DENTSPLY SIRONA's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Anika Therapeutics-5.18%2.63%1.91%
DENTSPLY SIRONA-1.40%7.13%4.13%

Earnings & Valuation

This table compares Anika Therapeutics and DENTSPLY SIRONA's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Anika Therapeutics$114.51 million5.12$27.19 million$2.0519.95
DENTSPLY SIRONA$4.03 billion3.54$262.90 million$2.4526.61

DENTSPLY SIRONA has higher revenue and earnings than Anika Therapeutics. Anika Therapeutics is trading at a lower price-to-earnings ratio than DENTSPLY SIRONA, indicating that it is currently the more affordable of the two stocks.

Summary

DENTSPLY SIRONA beats Anika Therapeutics on 8 of the 14 factors compared between the two stocks.

Anika Therapeutics (NASDAQ:ANIK) and Haemonetics (NYSE:HAE) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, dividends, valuation, profitability, risk, earnings and institutional ownership.

Risk and Volatility

Anika Therapeutics has a beta of 1.1, suggesting that its share price is 10% more volatile than the S&P 500. Comparatively, Haemonetics has a beta of 0.56, suggesting that its share price is 44% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Anika Therapeutics and Haemonetics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Anika Therapeutics00103.00
Haemonetics00403.00

Anika Therapeutics presently has a consensus target price of $43.00, suggesting a potential upside of 4.72%. Haemonetics has a consensus target price of $144.80, suggesting a potential upside of 23.51%. Given Haemonetics' higher possible upside, analysts clearly believe Haemonetics is more favorable than Anika Therapeutics.

Insider and Institutional Ownership

95.0% of Anika Therapeutics shares are held by institutional investors. Comparatively, 96.2% of Haemonetics shares are held by institutional investors. 2.5% of Anika Therapeutics shares are held by company insiders. Comparatively, 1.6% of Haemonetics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Anika Therapeutics and Haemonetics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Anika Therapeutics-5.18%2.63%1.91%
Haemonetics11.76%22.85%10.40%

Earnings & Valuation

This table compares Anika Therapeutics and Haemonetics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Anika Therapeutics$114.51 million5.12$27.19 million$2.0519.95
Haemonetics$988.48 million6.03$76.53 million$3.3135.43

Haemonetics has higher revenue and earnings than Anika Therapeutics. Anika Therapeutics is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks.

Summary

Haemonetics beats Anika Therapeutics on 11 of the 13 factors compared between the two stocks.

Anika Therapeutics (NASDAQ:ANIK) and Quidel (NASDAQ:QDEL) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, dividends, valuation, profitability, risk, earnings and institutional ownership.

Risk and Volatility

Anika Therapeutics has a beta of 1.1, suggesting that its share price is 10% more volatile than the S&P 500. Comparatively, Quidel has a beta of 0.45, suggesting that its share price is 55% less volatile than the S&P 500.

Profitability

This table compares Anika Therapeutics and Quidel's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Anika Therapeutics-5.18%2.63%1.91%
Quidel36.91%63.31%40.55%

Earnings & Valuation

This table compares Anika Therapeutics and Quidel's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Anika Therapeutics$114.51 million5.12$27.19 million$2.0519.95
Quidel$534.89 million10.38$72.92 million$2.7348.07

Quidel has higher revenue and earnings than Anika Therapeutics. Anika Therapeutics is trading at a lower price-to-earnings ratio than Quidel, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

95.0% of Anika Therapeutics shares are held by institutional investors. Comparatively, 84.0% of Quidel shares are held by institutional investors. 2.5% of Anika Therapeutics shares are held by company insiders. Comparatively, 14.1% of Quidel shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Anika Therapeutics and Quidel, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Anika Therapeutics00103.00
Quidel10302.50

Anika Therapeutics presently has a consensus target price of $43.00, suggesting a potential upside of 4.72%. Quidel has a consensus target price of $262.75, suggesting a potential upside of 103.60%. Given Quidel's higher possible upside, analysts clearly believe Quidel is more favorable than Anika Therapeutics.

Summary

Quidel beats Anika Therapeutics on 11 of the 14 factors compared between the two stocks.


Anika Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Align Technology logo
ALGN
Align Technology
1.9$598.14+0.4%$47.14 billion$2.41 billion27.21
West Pharmaceutical Services logo
WST
West Pharmaceutical Services
1.9$303.47+1.0%$22.63 billion$1.84 billion80.07
The Cooper Companies logo
COO
The Cooper Companies
1.9$389.18+0.4%$19.21 billion$2.43 billion80.91
DENTSPLY SIRONA logo
XRAY
DENTSPLY SIRONA
2.0$65.20+2.1%$13.99 billion$4.03 billion-283.48Decrease in Short Interest
Haemonetics logo
HAE
Haemonetics
1.6$117.28+0.2%$5.97 billion$988.48 million56.66
Quidel logo
QDEL
Quidel
2.4$131.22+1.2%$5.48 billion$534.89 million15.40
STAAR Surgical logo
STAA
STAAR Surgical
1.4$117.45+1.5%$5.38 billion$150.18 million618.19Increase in Short Interest
Neogen logo
NEOG
Neogen
1.2$94.12+0.9%$4.99 billion$418.17 million82.56
ICU Medical logo
ICUI
ICU Medical
1.5$208.90+1.4%$4.37 billion$1.27 billion55.26Insider Selling
Merit Medical Systems logo
MMSI
Merit Medical Systems
1.5$61.94+1.6%$3.39 billion$994.85 million-116.87
Atrion logo
ATRI
Atrion
1.1$649.65+0.7%$1.18 billion$155.07 million36.60
Cerus logo
CERS
Cerus
1.5$6.29+0.5%$1.05 billion$74.65 million-16.13News Coverage
Meridian Bioscience logo
VIVO
Meridian Bioscience
1.7$24.11+0.7%$1.05 billion$253.67 million22.32
OraSure Technologies logo
OSUR
OraSure Technologies
1.7$10.30+0.2%$742.48 million$154.60 million-44.78
Antares Pharma logo
ATRS
Antares Pharma
1.8$4.04+0.0%$679.37 million$123.86 million67.34
Utah Medical Products logo
UTMD
Utah Medical Products
0.9$88.57+1.5%$317.93 million$46.90 million27.94
This page was last updated on 4/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.